picibanil and Gallbladder-Neoplasms

In order to evaluate the combination therapy for liver and bile tract cancer, the effects of anticancer drugs and hyperthermia were observed using cultured human cancer cell lines. In the case of gall bladder cancer cell line (NOZ), combination of adriamycin and hyperthermia showed more effective inhibition for cell proliferation than MMC + hyperthermia and 5-FU + hyperthermia. Hepatocellular carcinoma cell line (JHH-4) showed remarkable inhibition of cell growth and secretion of albumin by combination treatment of adriamycin and hyperthermia. Morphologically, JHH-4 cells were enlarged and the nucleus was also enlarged with combination adriamycin and hyperthermia by phase contrast microscopy. Cytoskeleton of JHH-4 cells became irregular and intercellular borderline was unclear by plasma polymerization replica method (PPRM). The effects of BRM (OK-432 and TNF) on HCC cell lines was also investigated. OK-432 directly inhibited proliferation of JHH-4 cells. We observed internalization of OK-432 by JHH-4 cells with TEM and 16-mm movie. TNF showed various effects on human HCC cell lines. Proliferation of two cell lines was inhibited, and one tended to be enhanced after the addition of TNF to the medium. Hyperthermia influenced the effects of TNF to HCC cell lines. We think that this paper is a very significant study for improving the therapy for hepato-biliary cancers.

Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Combined Modality Therapy; Doxorubicin; Fluorouracil; Gallbladder Neoplasms; Humans; Hyperthermia, Induced; In Vitro Techniques; Liver Neoplasms; Mitomycin; Mitomycins; Picibanil; Tumor Necrosis Factor-alpha

Four patients with gallbladder cancer and two with bile duct cancer were treated with mitomycin C, carboquone, 5-fluorouracil and OK-432 (MQF-OK therapy) plus tegafur (FT) or UFT. MQF-OK therapy was administered according to our original method. FT and UFT were orally given in a dose of 600-800 mg/body/day and 300-400 mg/body/day, respectively. Three with gallbladder cancer and one with bile duct cancer showed PR. Myelosuppression was observed in all cases, but recovered in two weeks after MQF therapy. We recommend the further trial of MQF-OK therapy plus FT or UFT for gallbladder and bile duct cancer.

Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carbazilquinone; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Mitomycins; Picibanil; Tegafur; Uracil

Topics: Aged; Biological Products; Biopsy, Needle; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Pancreatic Neoplasms; Picibanil; Ultrasonography